Efficacy and Tolerability of Micronised Fenofibrate, 200 mg, Single-dose Daily Treatment for 12 Weeks in a Turkish Cohort of Dyslipidemic Patients

This Jtudy was conducted in /0 centres to evaluate tire efficacy and safety of micronizedfenofibirare il ı cı coft.ort of Tu rkish dyslipidemic patients. Ir was an open study wirlıour a control group. 98 patients (53% were women). were selecred and 72 patients between tlıe age group of 18 to 75 years (54±10.5). wir/ı rype Ila (n=25). rype /Ib (n=43) and rype IV (n=4) dyslipide111ia. ıvere l'olwrtarily included in the study. After ar leasr a 4-ıveek waslı-ow period wirlr a srandardised die ı. 200 mg once-daily dose ofmicronisedfenofibrate was given to parienis w!rose dyslipidemia was proven by laborarory test s. Efficacy and safety parameren were assessed at the begimıing and at tlıe 4tlı. 6tlı and 12tlı ıveeks of treamıelll in 72 patients wlıo completed tlıe study according to tlıe protocol. hı comparison to the baseline values, patiellts witlı type Ila dyslipidemia slıowed a decrease of /8.5% in total clı o/este ro/ (TC) /eve/. and 27.4% inlow density lipoprotein clıo lesterol (LDL-C) /eve/ and 32.6% (49.6% as median value) in triglyceride (TC) !eve/ and an increase of 19.7% inlıiglı density lipoprotein clıolestero/ (HDL-C) !evet after 12-week treatment. All tlıe ParialiO/ıs in Flı e lipid va/ues were coiiSidered statistically significant (pKeywords: Micronized fenofibrate, dyslipidemia. Hypertriglyceridemia